Becker's Hospital Review | Healthcare News & Analysis

Author's posts

UCI Health, Lifepoint Health break ground on California rehabilitation hospital

Orange, Calif.-based UCI Health and Lifepoint Rehabilitation — a Brentwood, Tenn.-based Lifepoint Health business unit — have broken ground on a new inpatient rehabilitation hospital in Irvine, Calif., as part of a joint venture partnership.

Vanderbilt latest system to adopt patient code of conduct

Nashville, Tenn.-based Vanderbilt University Medical Center is the latest system to adopt a patient code of conduct amid a national increase of violence against healthcare workers, the system announced Feb. 16.

Mercy Health to lay off some call center workers

Mercy Health has partnered with a third party to manage its contact center for primary care scheduling — a move that will affect a “number of call center positions,” a spokesperson for the Cincinnati-based system confirmed to Becker’s on Feb. 16. …

Former Hackensack Meridian co-CEO John Lloyd dies

John Lloyd, former co-CEO of Edison, N.J.-based Hackensack Meridian Health, has died, according to a Feb. 16 news release shared with Becker’s.

Nurse workforce shows signs of bouncing back

The nursing workforce is 6% larger in 2023 than in 2019, hinting at a bounce back to pre-pandemic numbers, a study found.

IT outage diverts stroke, trauma patients at Minnesota hospitals

Some Minnesota hospitals have had to divert stroke and trauma patients after an apparent cyberattack on a radiology group, the St. Paul (Minn.) Pioneer Press reported.

Readmissions down at Delaware health system after virtual nursing rollout

Newark, Del.-based ChristianaCare has rolled out virtual nursing at more than hospital 500 beds and experienced declines in patient lengths of stay and readmission rates.

FDA approves food allergy drug

The FDA has approved omalizumab, which goes by the brand name Xolair, as a treatment to reduce the risk of severe allergic reactions for those with food allergies. 

1st tumor-derived T cell therapy approved

A week ahead of schedule, the FDA approved the nation’s first cell therapy for advanced melanoma on Feb. 16. 

CommonSpirit strategy pays dividends, but CFO insists 'still more to do'

Chicago-based CommonSpirit is making significant strides to improve its financial performance — transforming a $440 million operating loss in the fourth quarter of 2022 into a $356 million gain in the fourth quarter of 2023 — but CFO Dan Morissette ins…